PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
Main Authors: | Cesar Rodriguez Valdes, Katja Weisel, Rachid Baz, Akshanth Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D’amico, Orlando F. Bueno, Leanne Lash Fleming, Peter Voorhees |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975144.60985.f9 |
Similar Items
-
P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Katja Weisel, et al.
Published: (2023-08-01) -
CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
by: Eyleen de Poel, et al.
Published: (2021-09-01) -
Two possible emendations of Beowulf 2088A
by: Pascual, RJ
Published: (2019) -
Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
by: John Powderly, et al.
Published: (2021-01-01) -
Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
by: David M. Foureau, et al.
Published: (2020-07-01)